by Carly Helfand |Jan 18, 2019 11:10am Should the FDA approve Sanofi’s SGLT1/2 candidate for patients with Type 1 diabetes? Turns out, the experts can’t agree. On Thursday, an advisory panel was split—voting 8-8—on whether the overall benefits of the drug, dubbed Zynquista, outweigh its risks. Now, it’ll be up to the FDA to decide […]
